BioXcel Therapeutics, Inc.
BTAINASDAQHealthcare● Active
$1.11
+$0.00(+0.00%)
Market Cap$34119748
P/E Ratio—
52W High$8.08
52W Low$1.01
BioXcel Therapeutics, Inc. (BTAI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BTAI · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.64M | $2.27M | $1.38M | $0.38M | $0.00M |
| Cost of Revenue | $0.16M | $2.14M | $1.26M | $0.02M | $0.00M |
| Gross Profit | $0.48M | $0.12M | $0.12M | $0.35M | $0.00M |
| Gross Margin %(computed) | 74.45% | 5.43% | 8.70% | 94.67% | — |
| Operating Expenses | |||||
| R&D Expenses | $30.25M | $30.43M | $84.33M | $91.24M | $52.71M |
| G&A Expenses | $20.09M | $33.10M | $63.51M | $55.76M | $54.23M |
| Total Operating Expenses | $50.74M | $67.37M | $171.90M | $160.00M | $106.94M |
| Operating Income | ($50.27M) | ($67.25M) | ($171.78M) | ($159.65M) | ($106.94M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $1.07M | $2.60M | $5.65M | $2.53M | $0.00M |
| Interest Expense | $16.98M | $15.13M | $13.31M | $8.21M | $0.04M |
| Income Before Tax | ($69.90M) | ($59.60M) | ($179.05M) | ($165.76M) | ($106.93M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($69.90M) | ($59.60M) | ($179.05M) | ($165.76M) | ($106.93M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.73 | $-23.51 | $-98.35 | $-94.67 | $-64.87 |
| Wtd Avg Shares | 12.21M | 2.54M | 1.82M | 1.75M | 1.65M |
| EBITDA | ($52.61M) | ($44.16M) | ($165.42M) | ($157.22M) | ($106.59M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more BioXcel Therapeutics, Inc. data
About BioXcel Therapeutics, Inc. (BTAI) Income Statement
BioXcel Therapeutics, Inc. (BTAI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BTAI reported revenue of $0.00B, gross profit of $0.00B (gross margin 74.45%), and net income of ($0.07B) — a net profit margin of -10887.38%.
Frequently asked questions
BTAI · 4 questionsBioXcel Therapeutics, Inc. (BTAI) reported revenue of $0.00B for 2025, down 71.7% year-over-year.
BTAI revenueBTAI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09